These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 32281470)

  • 21. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
    Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
    Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of norepinephrine on the outcome of septic shock.
    Martin C; Viviand X; Leone M; Thirion X
    Crit Care Med; 2000 Aug; 28(8):2758-65. PubMed ID: 10966247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal Trends and Clinical Outcomes Associated with Vasopressor and Inotrope Use in The Cardiac Intensive Care Unit.
    Jentzer JC; Wiley B; Bennett C; Murphree DH; Keegan MT; Kashani KB; Bell MR; Barsness GW
    Shock; 2020 Apr; 53(4):452-459. PubMed ID: 31169766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock.
    Patel GP; Grahe JS; Sperry M; Singla S; Elpern E; Lateef O; Balk RA
    Shock; 2010 Apr; 33(4):375-80. PubMed ID: 19851126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The medical treatment of cardiogenic shock: cardiovascular drugs.
    De Backer D; Arias Ortiz J; Levy B
    Curr Opin Crit Care; 2021 Aug; 27(4):426-432. PubMed ID: 33797431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasopressor and inotropic support in septic shock: an evidence-based review.
    Beale RJ; Hollenberg SM; Vincent JL; Parrillo JE
    Crit Care Med; 2004 Nov; 32(11 Suppl):S455-65. PubMed ID: 15542956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choice of vasopressor in septic shock: does it matter?
    Patel GP; Balk RA
    Crit Care; 2007; 11(6):174. PubMed ID: 18001504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
    Avni T; Lador A; Lev S; Leibovici L; Paul M; Grossman A
    PLoS One; 2015; 10(8):e0129305. PubMed ID: 26237037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Clinical Outcomes with Initial Norepinephrine or Epinephrine for Hemodynamic Support After Return of Spontaneous Circulation.
    Weiss A; Dang C; Mabrey D; Stanton M; Feih J; Rein L; Feldman R
    Shock; 2021 Dec; 56(6):988-993. PubMed ID: 34172611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vasopressor use in septic shock: an update.
    Leone M; Martin C
    Curr Opin Anaesthesiol; 2008 Apr; 21(2):141-7. PubMed ID: 18443479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
    Belletti A; Benedetto U; Biondi-Zoccai G; Leggieri C; Silvani P; Angelini GD; Zangrillo A; Landoni G
    J Crit Care; 2017 Feb; 37():91-98. PubMed ID: 27660923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inotrope and vasopressor use in cardiogenic shock: what, when and why?
    Hu K; Mathew R
    Curr Opin Crit Care; 2022 Aug; 28(4):419-425. PubMed ID: 35792520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials.
    Russell JA; Lee T; Singer J; De Backer D; Annane D
    J Crit Care; 2018 Oct; 47():333-337. PubMed ID: 29958734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial.
    Annane D; Vignon P; Renault A; Bollaert PE; Charpentier C; Martin C; Troché G; Ricard JD; Nitenberg G; Papazian L; Azoulay E; Bellissant E;
    Lancet; 2007 Aug; 370(9588):676-84. PubMed ID: 17720019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current concepts on hemodynamic support and therapy in septic shock.
    Rocha LL; Pessoa CM; Corrêa TD; Pereira AJ; de Assunção MS; Silva E
    Braz J Anesthesiol; 2015; 65(5):395-402. PubMed ID: 26323739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock.
    Hall LG; Oyen LJ; Taner CB; Cullinane DC; Baird TK; Cha SS; Sawyer MD
    Pharmacotherapy; 2004 Aug; 24(8):1002-12. PubMed ID: 15338849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.
    Jentzer JC; Coons JC; Link CB; Schmidhofer M
    J Cardiovasc Pharmacol Ther; 2015 May; 20(3):249-60. PubMed ID: 25432872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II in Refractory Septic Shock.
    Antonucci E; Gleeson PJ; Annoni F; Agosta S; Orlando S; Taccone FS; Velissaris D; Scolletta S
    Shock; 2017 May; 47(5):560-566. PubMed ID: 27879559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of equipressor doses of norepinephrine, epinephrine, and phenylephrine on septic myocardial dysfunction.
    Ducrocq N; Kimmoun A; Furmaniuk A; Hekalo Z; Maskali F; Poussier S; Marie PY; Levy B
    Anesthesiology; 2012 May; 116(5):1083-91. PubMed ID: 22407285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic Agents for the Treatment of Vasodilatory Shock.
    Knotzer H; Poidinger B; Kleinsasser A
    Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.